Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes

Antiviral Research

Volumn 77, Issue 2, 2008, Pages 163-166

  Abed, Yacine ^a   Nehmé, Benjamin ^a   Baz, Mariana ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

A 315675; Influenza; Neuraminidase inhibitors; Oseltamivir; Resistance

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; A 315675; A 322278; ANTIVIRUS AGENT; METHYLUMBELLIFERYL N ACETYLNEURAMINIC ACID; OSELTAMIVIR; PERAMIVIR; PRODRUG; RECOMBINANT PROTEIN; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ARTICLE; IC 50; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INHIBITORY CONCENTRATION 50; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PYRROLIDINES; RECOMBINANT PROTEINS; TRANSFECTION;

ORTHOMYXOVIRIDAE;

EID: 38149139549     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.08.008     Document Type: Article

References (38)

1. Abed Y., Goyette N., and Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9 (2004) 577-581
2. Abed Y., and Boivin G. Treatment of respiratory virus infections. Antiviral Res. 70 (2006) 1-16
3. Abed Y., Baz M., and Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11 (2006) 971-976
4. Bantia S., Arnold C.S., Parker C.D., Upshaw R., and Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69 (2006) 39-45
5. Barnes D.M., Bhagavatula L., DeMattei J., Gupta A., Hill D.R., Manna S., McLaughlin M.A., Nichols P., Premchandran R., Rasmussen M.W., Tian Z., and Wittenberger S.J. A highly diastereoselective vinylogous Mannich condensation and 1,4-conjugate addition of (Z)-propenyl cuprate in the synthesis of an influenza neuraminidase inhibitor. Tetrahedron: Asymmetry 14 (2003) 3541-3551
6. Barroso L., Treanor J., Gubareva L., and Hayden F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir. Ther. 10 (2005) 901-910
7. Baz M., Abed Y., McDonald J., and Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during one year by an immunocompromised child. Clin. Infect. Dis. 43 (2006) 1555-1561
8. Baz M., Abed Y., and Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 74 (2007) 159-162
9. DeGoey D.A., Chen H.J., Flosi W.J., Grampovnik D.J., Yeung C.M., Klein L.L., and Kempf D.J. Enantioselective synthesis of anti-influenza compound A-315675. J. Org. Chem. 67 (2002) 5445-5453
10. De Jong M.D., Thanh T.T., Khahn T.H., Vo M.H., Smith G.J., Nguyen V.C., and Bach V.C. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353 (2005) 2667-2672
11. Goto H., Bethell R.C., and Kawaoka Y. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 238 (1997) 265-272
12. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., and Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001) 523-531
13. Gubareva L.V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103 (2004) 199-203
14. Hatakeyama S., Sugaya N., Ito M., Yamazaki M., Ichikawa M., Kimura K., Kiso M., Shimizu H., Kawakami C., Koike K., Mitamura K., and Kawaoka Y. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Lancet 297 (2007) 1435-1442
15. Hayden F.G., Kilmov A., Tashiro M., Hay A., Monto A., McKimm-Breschkin J., Macken C., Hampson A., Webster R.G., Aymard M., and Zambon M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir. Ther. 10 (2005) 873-878
16. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., and Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190 (2004) 1627-1630
17. Hurt A.C., Selleck P., Komadina N., Shaw R., Brown L., and Barr I.G. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73 (2007) 228-231
18. Ison M.G., Mishin V.P., Braciale T.J., Hayden F.G., and Gubareva L.V. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J. Infect. Dis. 193 (2006) 765-772
19. Ison M.G., Gubareva L.V., Atmar R.L., Treanor J., and Hayden F.G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193 (2006) 760-764
20. Jackson H.C., Roberts N., Wang Z.M., and Belshe R. Management of influenza. Use of new antivirals and resistance in perspective. Clin. Drug Invest. 20 (2000) 447-454
21. Kati W.M., Montgomery D., Carrick R., Gubareva L.V., Maring C., McDaniel K., Stefy K., Molla A., Hayden F.G., Kempf D., and Kohlbrenner W. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46 (2002) 1014-1021
22. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., and Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364 (2004) 759-765
23. Le Q.M., Kiso M., Someya K., Yuko T., Sakai T., Nguyen T.H., Nguyen K.H.L., Pham N.D., Ngyen H.H., Yamada S., Horimoto T., Takada A., Goto H., Suzuki T., and Kawaoka Y. Isolation of drug-resistant H5N1 virus. Nature 437 (2005) 1108
24. Maring C.J., Stoll V.S., Zhao C., Sun M., Krueger A.C., Stewart K.D., Madigan D.L., Kati W.M., Xu Y., Carrick R.J., Montgomery D.A., Kempf-Grote A., Marsh K.C., Molla A., Steffy K.R., Sham H.L., Laver W.G., Gu Y.G., Kempf D.J., and Kohlbrenner W.E. Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. J. Med. Chem. 48 (2005) 3980-3990
25. Mishin V.P., Hayden F.Y., and Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49 (2005) 4515-4520
26. Molla A., Kati W., Carrick R., Stefy K., Shi Y., Montgomery D., Gusick N., Stoll V.S., Stewart K.D., Maring C., Kempf D., and Kohlbrenner W. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 76 (2002) 5380-5386
27. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymar M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
28. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2006) 1363-1373
29. Potier M., Mameli L., Belisle M., Dallaire L., and Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Ann. Biochem. 94 (1979) 287-296
30. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
31. Sidwell R.W., and Smee D.F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin. Investig. Drugs 11 (2002) 859-869
32. Wang M.Z., Tai C.Y., and Mendel D.B. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46 (2002) 3809-3816
33. Ward P., Small I., Smith J., Suter P., and Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55 (2005) i5-i21
34. Weinstock D.M., Gubareva L.V., and Zucotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348 (2003) 867-868
35. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20 (2001) 127-133
36. World Health Organisation. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitors resistance. Wkly. Epidemiol. Rec. 80 (2005) 156
37. World Health Organisation, 2006. WHO rapid advice guidelines on pharmacological management of human infected with avian influenza A (H5N1) virus. Available at http://www.who.int/medicines/publications/WHO_PSM_PAR_2006.6.pdf.
38. Yen H., Monto A.S., Webster R.G., and Govorkova E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192 (2005) 665-672